title: D2 prostate cancer--half dosage of the LHRH-agonists is sufficient for complete androgen deprivation.
authors.forename: A
authors.initials: A
authors.lastname: Jungwirth
authors.forename: D
authors.initials: D
authors.lastname: Mack
authors.forename: J
authors.initials: J
authors.lastname: Frick
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000726:Androgen Antagonists / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D013739:Testosterone / Q000037:antagonists & inhibitors; D017329:Triptorelin Pamoate / Q000008:administration & dosage*
chemical_list: D000726:Androgen Antagonists; D017329:Triptorelin Pamoate; D013739:Testosterone